TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.45
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.05

31 Jul
2025

0.370

OPEN

$20.89

1.79%

HIGH

$21.21

1,373,921

LOW

$20.69

TARGET
$35.00 66.3% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) 36.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 54.8 xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx15.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx783.2 M
Book Value Per Share xxxxxxxxxxxxxxx169.8
Net Operating Cash Flow xxxxxxxxxxxxxxx43.0 M
Net Profit Margin xxxxxxxxxxxxxxx6.37 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx13.92 %
Return on Invested Capital xxxxxxxxxxxxxxx7.72 %
Return on Assets xxxxxxxxxxxxxxx5.18 %
Return on Equity xxxxxxxxxxxxxxx13.92 %
Return on Total Capital xxxxxxxxxxxxxxx12.46 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx560 M
Total Debt xxxxxxxxxxxxxxx581 M
Goodwill - Gross xxxxxxxxxxxxxxx107 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx710 M
Price To Book Value xxxxxxxxxxxxxxx14.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx48.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx273 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx428 M
Research & Development xxxxxxxxxxxxxxx195 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

23/07/2025

1

Buy

$36.00

71.02%

UBS views Telix Pharmaceuticals' 2Q25 trading update as "solid" with group revenue at US$204m and Illuccix achieving US$154m, which was in line with consensus and slightly lower than the broker's forecast at US$163m.

Notably, dose volume rose by 7%, which infers the uptake and penetration into the prostrate diagnostic market continues. 

UBS believes the company has managed the launch of Gozellix in June with the assignment of a HCPCS code (Healthcare Common Procedure Coding System) despite pricing issues.

Management's 2025 guidance of US$770m-US$800m is achievable, the broker explains. UBS spoke with management who explained a dual listing on the ASX and Nasdaq brings forth different disclosure terms, and the SEC's subpoena is a fact-finding exercise.

The inquiry does not extend to its diagnostics franchise or to prostate therapeutic candidates. Uncertainty over the timing of resolution and outcome remains.

Buy. Target unchanged at $36.

FORECAST
UBS forecasts a full year FY25 dividend of 0.00 cents and EPS of 36.00 cents.
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 76.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

12/05/2025

1

Overweight

$35.00

66.27%

Telix Pharmaceuticals' competitor Lantheus reported 1Q25 results where revenue of US$257.7m missed Wilsons' forecast by -5%.

The broker estimates Lantheus lost -200bps of market share and cited competitive disruption as a reason. Telix pharma's 1Q25 revenue, on the other hand, was 5% ahead of the broker's forecast due mainly to stronger debut of RLS radiopharmacies.

The broker believes Lantheus' result confirms its positive outlook for Telix Pharma's and Illuccix/Goellix are well-positioned to gain more market share as the PSMA market continues to expand.

Overweight. Target unchanged at $35.

The broker previously flagged it will update forecasts after the company releases USD-denominated historical forecasts.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 31.20 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 58.80 cents.
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
In Brief: South32, Telix & Generation Development

Jul 25 2025 - Weekly Reports
2
Rudi’s View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Jul 24 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Jul 24, 2025

Jul 24 2025 - Daily Market Reports
4
Rudi’s View: Extreme Bifurcation Ahead Of August

Jul 23 2025 - Rudi's View
5
Rudi’s View: Aussie Broadband, oOh!media, Paladin Energy, Seek, Xero & More

Jul 17 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
2
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
3
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
4
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
5
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
6
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
7
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
8
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
9
CSL Shares Breaking Free

Jul 23 2024 - Technicals
10
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps